Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab
about
Markers of Response to Antiangiogenic Therapies in Colorectal Cancer: Where Are We Now and What Should Be Next?Recent applications of chemosensitivity tests for colorectal cancer treatmentAssociation between Polymorphisms in Vascular Endothelial Growth Factor Gene and Response to Chemotherapies in Colorectal Cancer: A Meta-AnalysiseNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial.Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer.Development of individualized anti-metastasis strategies by engineering nanomedicinesEvidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients.IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patientsPrognostic and predictive role of vascular endothelial growth factor polymorphisms in breast cancer.Prognostic factors for survival with bevacizumab-based therapy in colorectal cancer patients: a systematic review and pooled analysis of 11,585 patients.Pharmacogenetics and breast cancer management: current status and perspectives.Methods: for studying pharmacogenetic profiles of combination chemotherapeutic drugs.The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives.MiR-718 represses VEGF and inhibits ovarian cancer cell progression.Biology and therapeutic implications of VEGF-A splice isoforms and single-nucleotide polymorphisms in colorectal cancer.Validation of VEGFR1 rs9582036 as predictive biomarker in metastatic clear-cell renal cell carcinoma patients treated with sunitinib.Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer.Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study.Role of VEGFA gene polymorphisms in colorectal cancer patients who treated with bevacizumab."Vessels in the Storm": Searching for Prognostic and Predictive Angiogenic Factors in Colorectal Cancer.Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy.Biomaterials for Abrogating Metastasis: Bridging the Gap between Basic and Translational Research.Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab.Genetic variations in the VEGF pathway as prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy.and Deleterious Mutations and Deletion Predict Bevacizumab Resistance in Metastatic Colorectal Cancer Patients
P2860
Q26752752-08E5A075-6B0D-423E-B648-848812719A89Q26851075-82B46D54-F178-45D2-BEFE-DE603D486913Q26862559-C8F0A421-914A-43B6-ADA1-487EC240C088Q30986269-C8E13A3B-F1AB-4DC2-A6FA-1C3AB48F53D3Q34492273-4B223970-915C-4DAE-9AAF-C8342C901122Q35967474-81CF8246-ACF8-4CC5-9174-9E18936C6D23Q37408810-678668B9-F524-4E36-98B0-7A72828E339FQ37725536-BE063B48-DBC5-4506-AA70-18B7C734B9AAQ38308001-C22F88EC-01AB-4EF7-9839-C0540ACC0254Q38312076-ED8FD363-2424-45C6-B14E-F618C46CD26FQ38358816-6256545C-6BBD-4429-8C04-C04DC7ABC3A4Q38513661-7570E646-75E6-4AAE-AAEE-AC0B8DBD2326Q38550459-1C602AF2-24FB-481C-9452-B78F5104259DQ38996307-8B84A6B6-86F6-42C9-A1C2-0A88E8FD9105Q39036253-BD722D5D-C2A8-4D28-86E3-D3C0870B3AAAQ39601152-A6274FC5-9A7B-4975-9F94-C34646AE1290Q45935444-80F30D77-BB8C-4608-9E21-A26E481CC7AEQ46721561-2CFB510E-096B-45BF-B184-F3A6386476D7Q47150792-66FB58EB-908C-4D3E-9384-A6406FDE40DCQ48207420-608E6F57-5636-46DC-BE6E-9B19FC1D7B41Q48848074-DFBCB124-D6CD-4A47-A482-2B8B843A4B77Q51231785-E9990179-F87F-4C60-A0C0-E0479B042600Q54180020-FE644F25-D44C-457A-A902-5B415C9CCF1DQ55067016-B1C95E5F-1905-47F1-9289-687081F0BC41Q58761037-F39FCFE5-65F8-488F-B841-AE563D8B6C75
P2860
Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Prospective validation of cand ...... -line FOLFIRI plus bevacizumab
@ast
Prospective validation of cand ...... -line FOLFIRI plus bevacizumab
@en
Prospective validation of cand ...... -line FOLFIRI plus bevacizumab
@nl
type
label
Prospective validation of cand ...... -line FOLFIRI plus bevacizumab
@ast
Prospective validation of cand ...... -line FOLFIRI plus bevacizumab
@en
Prospective validation of cand ...... -line FOLFIRI plus bevacizumab
@nl
prefLabel
Prospective validation of cand ...... -line FOLFIRI plus bevacizumab
@ast
Prospective validation of cand ...... -line FOLFIRI plus bevacizumab
@en
Prospective validation of cand ...... -line FOLFIRI plus bevacizumab
@nl
P2093
P2860
P50
P1433
P1476
Prospective validation of cand ...... -line FOLFIRI plus bevacizumab
@en
P2093
Carlotta Antoniotti
Chiara Cremolini
Ferdinando De Vita
Francesco Graziano
Giuseppe Aprile
Leonor Benhaim
Pierre Bohanes
Sara Lucchesi
Takeru Wakatsuki
P2860
P304
P356
10.1371/JOURNAL.PONE.0066774
P407
P50
P577
2013-07-04T00:00:00Z